Tvardi Therapeutics (NASDAQ:TVRD) Shares Down 83.9% After Analyst Downgrade

Key Points

• Tvardi Therapeutics shares plummeted 83.9% after BTIG Research downgraded the price target from $55.00 to $15.00, despite maintaining a buy rating.
• Multiple research firms have issued mixed ratings, with Cantor Fitzgerald and Piper Sandler downgrading to "neutral," while Barclays and Raymond James started coverage with higher price targets.
• The company's recent earnings report showed losses of ($1.00) per share, significantly missing analysts' estimates, highlighting concerns about a negative return on equity of 565.83%.

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) traded down 83.9% on Monday after BTIG Research lowered their price target on the stock from $55.00 to $15.00. BTIG Research currently has a buy rating on the stock. Tvardi Therapeutics traded as low as $5.65 and last traded at $6.69. 6,316,128 shares traded hands during mid-day trading, an increase of 8,634% from the average session volume of 72,314 shares. The stock had previously closed at $41.60.

A number of other research firms have also weighed in on TVRD. Cantor Fitzgerald lowered Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. Barclays started coverage on Tvardi Therapeutics in a report on Monday. They issued an "overweight" rating and a $61.00 target price for the company. Piper Sandler lowered Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. Raymond James Financial started coverage on Tvardi Therapeutics in a report on Monday, July 14th. They issued an "outperform" rating and a $62.00 target price for the company. Finally, Weiss Ratings reissued a "sell (e)" rating on shares of Tvardi Therapeutics in a report on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Tvardi Therapeutics has an average rating of "Hold" and a consensus price target of $46.17.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics during the second quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics during the second quarter valued at about $43,000. Headlands Technologies LLC bought a new stake in Tvardi Therapeutics during the second quarter valued at about $80,000. New York State Common Retirement Fund bought a new stake in Tvardi Therapeutics during the second quarter valued at about $92,000. Finally, Bank of America Corp DE bought a new stake in Tvardi Therapeutics during the second quarter valued at about $399,000. 44.66% of the stock is owned by institutional investors.

Tvardi Therapeutics Price Performance

The stock's fifty day moving average price is $31.63.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.